According to a report by D'Avila et al., baseline AMH below 1.87 ng/ml could be used as an indicator of the risk of amenorrhea in women with breast cancer after the treatment with chemotherapy, and since amenorrhea indicates permanent impairment of ovaries, women of childbearing age with a baseline AMH below 3.32 ng/ml must be provided with various fertility preservation strategies against the possible impaired fertility after chemotherapy [27]. The gene discussed is AMH; the disease is breast carcinoma.